Under the guidance of Prof. Peter M. Villiger our colleagues from the Department of Rheumatology, Immunology and Allergology have published an interesting, phase 2, randomised, double-blind, placebo-controlled study about the use of Tocilizumab for the treatment of giant cell arteritis in The Lancet. We congratulate the authors to this remarkable achievment!!!